This module explores some of the key Phase 3 efficacy and safety data from a number of different trials on canagliflozin, dapagliflozin and empagliflozin either as a monotherapy or in conjunction with other oral antidiabetic drugs and/or insulin. The associated advantages and adverse events are discussed and data from real-world evidence studies are introduced.
Assessment will rely in part on learners having read the following article referenced in this module.
By the end of this module, you will be able to:
✓ Explain the key efficacy data from the Phase 3 trials of SGLT-2 inhibitors in people with type 2 diabetes
✓ Identify the safety and adverse event profile of SGLT-2 inhibitors in people with type 2 diabetes
✓ Apply current guidelines to typical patients with type 2 diabetes who may benefit from treatment with SGLT-2 inhibitors as an adjunct to other therapies for type 2 diabetes
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.